Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Amanda Teeple & Timothy Fitzgerald. (2022) Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis. Journal of Dermatological Treatment 33:1, pages 518-524.
Read now
Read now
Amanda Teeple & Erik Muser. (2019) Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis. Journal of Medical Economics 22:12, pages 1268-1273.
Read now
Read now
Lluís Puig, Jaume Notario, Alberto Jiménez-Morales, David Moreno-Ramírez, Anna López-Ferrer, Irmina Gozalbo, Míriam Prades, Luis Lizán & Carles Blanch. (2017) Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. Journal of Dermatological Treatment 28:7, pages 623-630.
Read now
Read now
Marjan Massoudi, Mark Balk, Hongbo Yang, Cat N. Bui, Bhavik J. Pandya, Jenny Guo, Yan Song, Eric Q. Wu, Bruce Brown, Arie Barlev & Scott Flanders. (2017) Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Journal of Medical Economics 20:2, pages 121-128.
Read now
Read now
Atsuyuki Igarashi, Hiroyo Kuwabara, Kyle Fahrbach & Brad Schenkel. (2013) Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. Journal of Dermatological Treatment 24:5, pages 351-355.
Read now
Read now
Elizabeth E Uhlenhake & David A Mehregan. (2011) Ustekinumab: differential use in psoriasis. Clinical, Cosmetic and Investigational Dermatology 4, pages 93-99.
Read now
Read now
Articles from other publishers (13)
Miriam Zidane, Corinna Dressler, Matthew Gaskins & Alexander Nast. (2019) Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. JAMA Dermatology 155:12, pages 1380.
Crossref
Crossref
Steven R Feldman, Corey L Pelletier, Kathleen L Wilson, Rina K Mehta, Matthew A Brouillette, David Smith & Machaon M Bonafede. (2019) Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. Journal of Comparative Effectiveness Research 8:1, pages 45-54.
Crossref
Crossref
Christian Kromer, Daniel Celis, Diana Sonntag & Wiebke K. Peitsch. (2018) Biologicals and small molecules in psoriasis: A systematic review of economic evaluations. PLOS ONE 13:1, pages e0189765.
Crossref
Crossref
Mandy Gutknecht, Magdalene Krensel & Matthias Augustin. (2016) Health economic analyses of psoriasis management: a systematic literature search. Archives of Dermatological Research 308:9, pages 601-616.
Crossref
Crossref
Lorenzo Mantovani, Massimo Medaglia, Patrizio Piacentini, Marcella Tricca, Gino Antonio Vena, Antonietta Vozza, Gabriella Castellino & Alessandro Roccia. (2016) Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and Therapy 6:2, pages 151-167.
Crossref
Crossref
L. Puig, A. López-Ferrer, E. Vilarrasa, I. García & R. Fernández-del-Olmo. (2016) Model for Assessing the Efficiency of Biologic Drugs in the Treatment of Moderate to Severe Psoriasis for 1 Year in Clinical Practice in Spain. Actas Dermo-Sifiliográficas (English Edition) 107:1, pages 34-43.
Crossref
Crossref
L. Puig, A. López-Ferrer, E. Vilarrasa, I. García & R. Fernández-del Olmo. (2016) Modelo de eficiencia de los fármacos biológicos en el tratamiento de la psoriasis moderada-grave durante un año en las condiciones de uso en España. Actas Dermo-Sifiliográficas 107:1, pages 34-43.
Crossref
Crossref
Wei Zhang, Nazrul Islam, Canice Ma & Aslam H. Anis. (2014) Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis. PharmacoEconomics 33:4, pages 327-340.
Crossref
Crossref
L. Puig, A. López-Ferrer & E. Vilarrasa. (2014) Incremental Cost-Effectiveness Ratio Analysis of Biologic Treatments for Psoriasis at Clinically Significant Evaluation Time Points. Actas Dermo-Sifiliográficas (English Edition) 105:10, pages 951-953.
Crossref
Crossref
L. Puig, A. López-Ferrer & E. Vilarrasa. (2014) Análisis de coste-eficacia incremental de los tratamientos biológicos para la psoriasis en los momentos de valoración significativos para la práctica clínica. Actas Dermo-Sifiliográficas 105:10, pages 951-953.
Crossref
Crossref
Josephine Mauskopf, Miny Samuel, Doreen McBride, Usha G. Mallya & Steven R. Feldman. (2014) Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines. PharmacoEconomics 32:4, pages 395-409.
Crossref
Crossref
Reginald Villacorta, Joel W. Hay & Andrew Messali. (2013) Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. PharmacoEconomics 31:9, pages 823-839.
Crossref
Crossref
Jamie D. Croxtall. (2011) Ustekinumab. Drugs 71:13, pages 1733-1753.
Crossref
Crossref